Differential expression of MARK4 protein and related perturbations in females with ovulatory PCOS.
CONCLUSION: Reduced expression of MARK4 protein in OPCOS increases the associated risk of hyperlipidemia, hyperandrogenism and metabolic syndrome and thus the protein holds strong candidature as a drug target for the syndrome.
PMID: 31322078 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
More News: Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Insulin | Melanoma | Metabolic Syndrome | Ovaries | Polycystic Ovary Syndrome | Skin Cancer | Study | Zinc